Korean Pharmaceutical Industry Faces 3.6 Trillion Won Annual Loss from Government's Generic Drug Price Cut Plan

Korea's pharmaceutical industry is mounting fierce opposition to the government's plan to slash generic drug prices, warning of devastating financial losses and potential job cuts that could reshape the sector's future.

The Ministry of Health and Welfare announced plans to reduce the reimbursement price of generic drugs from the current 53.55 percent of original branded medicines to 40 percent, with implementation scheduled for the second half of 2026. The government justifies the measure as necessary for curbing healthcare costs and improving patient access, citing a similar 2012 price cut that reduced annual drug spending by approximately 1.46 trillion won ($1 billion).

Industry Projects Massive Financial Impact

The pharmaceutical sector has responded by forming an emergency committee comprising five major organizations: Korea Pharmaceutical and Bio-Pharma Manufacturers Association, Korea Bio-Pharmaceutical Association, Korea Pharmaceutical Traders Association, Korea Drug Research Association, and Korea Pharmaceutical Industry Cooperative.

"If we lower the price of generic drugs to 40 percent in accordance with the government's plan, (the pharmaceutical industry) projects an annual loss of up to 3.6 trillion won," said Yun Woong-sup during a press conference at the KPBMA's headquarters in Seoul. This estimate significantly exceeds the government's projections, representing more than three times the Ministry of Health and Welfare's calculations.

The industry's financial concerns are grounded in already thin profit margins. Among Korea's top 100 pharmaceutical companies, the average operating profit rate stands at just 4.8 percent, with net profit rates at 3 percent. Yun characterized the government's pricing revision as "a declaration to give up the domestic pharmaceutical industry's future."

Employment and R&D Investment at Risk

Beyond immediate financial impacts, the emergency committee warns that the proposed price cuts could eliminate 14,800 jobs, representing just over 10 percent of the Korean pharmaceutical sector's workforce. The industry argues that reduced profitability will inevitably lead to decreased investment in research and development for new drugs.

The pricing structure would fundamentally alter market dynamics. Under the proposed system, a generic version of a high blood pressure medication originally priced at 10,000 won would drop from the current 5,355 won to 4,000 won, representing a 25 percent reduction from existing generic prices.

International Price Comparisons Fuel Opposition

Industry representatives argue that Korean drug prices are already among the world's lowest, leaving little room for further reductions. According to analysis by the Korea Pharmaceutical and Biological Association, when Korean antibiotic prices are set at 1, equivalent medications cost 3.34 times more in the United States, 1.81 times more in Germany, and 1.73 times more in Canada, after adjusting for price levels.

"Developed countries guarantee appropriate drug prices for the protection of their pharmaceutical industry and the stable supply of essential drugs," an industry official stated. "To cut domestic drug prices further, which is already the lowest in the world, is like saying to close the business."

Long-term Supply Concerns

Industry sources warn that while patients may initially benefit from reduced medication costs and improved National Health Insurance structure, the long-term consequences could prove more severe. Mid-sized pharmaceutical firms may cease production of certain generic drugs due to low profitability, potentially forcing patients to travel further to access needed medications.

The emergency committee also highlighted that the 2012 drug price cut, while achieving short-term savings, ultimately led to a 13.8 percent increase in drug spending over time. They argue that the current proposal could drive some manufacturers out of business, leaving larger firms with reduced resources for new drug development and potentially compromising medical sovereignty.

The government maintains that the reform includes "a reward system that corresponds to the degree of investments for innovation and medical security," positioning the changes as a stepping stone for the domestic pharmaceutical industry's development. However, the industry's unified opposition suggests a prolonged battle ahead as both sides prepare for implementation discussions leading up to the 2026 deadline.